Dr. Gregory H Miller, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Suite 212a, Abingdon, VA 24211 Phone: 276-258-3740 Fax: 276-258-3745 |
John Byron Patterson, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Suite 212a, Abingdon, VA 24211 Phone: 276-258-3740 Fax: 276-258-3745 |
Dr. Lacyoni Moraes-finglass, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1237 W Main St, Abingdon, VA 24210 Phone: 276-676-2211 |
Dr. Larry H Cox, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 616 Campus Drive, Suite 300, Abingdon, VA 24210 Phone: 276-739-0067 Fax: 276-739-0069 |
Eduardo Fernandez, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 24530 Falcon Place Blvd, Suite 101, Abingdon, VA 24211 Phone: 276-739-0067 Fax: 276-739-0069 |
News Archive
People suffering from paralysis due to stroke or traumatic brain injury may be able to reprogram their brains to improve motor skills and to control artificial limbs, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospital faster, visit their doctors less for follow up care and take fewer medicines than those who underwent open surgery.
Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.
State legislatures around the country consider the implications of Medicaid expansion proposals under the federal health overhaul.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.
› Verified 4 days ago